Monoclonal antibodies lead the HER2 therapy market with a 42.0% share by drug class in 2026, followed by HER2-positive breast cancer at 61.0% by indication and injectable therapies at 74.0% by route of administration. Adoption depends on broader biomarker-based patient eligibility, while treatment resistance and access barriers remain a hurdle.
Her2 Therapy Market Analysis By Distribution ChannelHer2 Therapy Market Analysis By IndicationHer2 Therapy Market Analysis By Route Of AdministrationHer2 Therapy Market Opportunity Matrix Growth Vs ValueHer2 Therapy Market Breakdown By Drug Class, Indication, And Region